Relationship between serum ferritin levels and hepatic and renal function parameters in patients with transfusion-dependent β-thalassemia major: a hospital-based cross-sectional study

Rahul Garg; Mandayal Jamatia; Ritesh Vishwakarma

doi:10.18203/2320-6012.ijrms20263520

Authors

Rahul Garg Department of Medical Biochemistry, Index Medical College Hospital and Research Centre, Malwanchal University, Indore, Madhya Pradesh, India
Mandayal Jamatia Department of Biochemistry, Jaipur National University Institute of Medical Sciences and Research Centre, Jaipur, Rajasthan, India
Ritesh Vishwakarma Department of Medical Biochemistry, Index Medical College Hospital and Research Centre, Malwanchal University, Indore, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263520

Keywords:

Beta-thalassemia major, Blood transfusion, Iron overload, Kidney function tests, Liver function tests, Serum ferritin

Abstract

Background: Transfusion-dependent β-thalassemia major requires lifelong blood transfusions, resulting in iron overload and hepatic and renal complications. Serum ferritin is widely used as a surrogate marker of body iron stores. This study evaluated serum ferritin levels and their association with hepatic and renal function parameters in patients with transfusion-dependent β-thalassemia major.

Methods: This hospital-based cross-sectional study included 100 patients with transfusion-dependent β-thalassemia major. Demographic data were recorded, and serum ferritin, liver function tests, and renal function parameters were analyzed using laboratory methods. Data were analyzed using descriptive statistics and Pearson’s correlation analysis.

Results: The mean serum ferritin level was 2701.48±1393.83 ng/ml, with 46% of patients exhibiting ferritin concentrations >2500 ng/ml. Hepatic abnormalities included elevated AST (72%), ALT (60%), bilirubin (55%), and ALP (33%). Renal assessment revealed reduced estimated glomerular filtration rate (eGFR) in 35% of patients, while elevated serum creatinine and blood urea nitrogen were observed in 17% and 13%, respectively. Serum ferritin showed weak but statistically significant negative correlations with ALT (r=−0.227, p=0.023) and total bilirubin (r=−0.273, p=0.006), whereas no significant correlation was found with serum creatinine.

Conclusions: Patients with transfusion-dependent β-thalassemia major demonstrated substantial iron overload with frequent hepatic and renal biochemical abnormalities. Regular monitoring of serum ferritin together with liver and renal function tests may facilitate early detection of organ involvement and optimization of iron-chelation therapy.

References

Musallam KM, Cappellini MD, Porter JB, Farmakis D, Eleftheriou A, Angastiniotis M, et al. TIF guidelines for the management of transfusion-dependent β-thalassemia. HemaSphere. 2025;9(3):e70095.

Taher AT, Farmakis D, Porter JB, Cappellini MD, Musallam KM, eds. Guidelines for the management of transfusion-dependent β-thalassaemia (TDT). 5th edn. Nicosia (Cyprus): Thalassaemia International Federation; 2025.

Angastiniotis M, Petrou M, Loukopoulos D, Modell B, Farmakis D, Englezos P, et al. The prevention of thalassemia revisited. Hemoglobin. 2021;45(1):5-12.

Angastiniotis M, Lobitz S. Thalassemias: an overview. Int J Neonat Screen. 2019;5(1):16.

Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol. 2020;105(6):692-703.

Musallam KM, Lombard L, Kistler KD, Arregui M, Gilroy KS, Chamberlain C, et al. Epidemiology of clinically significant forms of alpha‐and beta‐thalassemia: a global map of evidence and gaps. Am J Hematol. 2023 Sep;98(9):1436-51.

Aziz SS, Hamad BK, Hamad HO, Qader MI, Ali EN, Muhammed RH, et al. Estimation of the prevalence of hemoglobinopathies in Iraq. Iraqi J Hematol. 2022;11(1):1-8.

Al-Allawi NA, Hassan K, Sheikha AK, Nerweiy FF, Dawood RS, Jubrael J. β-Thalassemia mutations among transfusion-dependent thalassemia major patients in Northern Iraq. Mol Biol Int. 2010;2010:479282.

Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the EPIC study of deferasirox in transfusion-dependent anemias. Haematologica. 2010;95(4):557-66.

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118(4):884-93.

Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.

Borgna-Pignatti C, Meloni A, Guerrini G, Gulino L, Filosa A, Ruffo GB, et al. Myocardial iron overload in thalassemia major: assessment by magnetic resonance imaging. Br J Haematol. 2014;164(4):579-85.

Aydinok Y, Evans P, Manz CY, Porter JB. Timed non-transferrin-bound iron determinations and response to iron chelation therapy in transfusion-dependent β-thalassemia. Haematologica. 2012;97(6):835-41.

Musallam KM, Taher AT. Luspatercept: a treatment for ineffective erythropoiesis in thalassemia. Hematology Am Soc Hematol Educ Program. 2024;2024(1):419-25.

Borgna-Pignatti CA, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.

Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-9.

Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-55.

Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81-5.

Angelucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M, Muretto P, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90(12):4736-42.

Au WY, Lam WW, Chu WW, Yuen HL, Ling AS, Li RC, et al. A cross-sectional magnetic resonance imaging assessment of organ-specific hemosiderosis in 180 patients with thalassemia major. Haematologica. 2008;93(5):784-6.

Meloni A, Pistoia L, Putti MC, Longo F, Corigliano E, Ricchi P, et al. Pancreatic iron in pediatric transfusion-dependent β-thalassemia patients: a longitudinal MRI study. Pediatr Blood Cancer. 2024;71:e31245.

Mekkey SM, Ameen MA, Hadi NK. A study of serum levels of ferritin, hepatic and renal functions in beta-thalassemia major (BTM) patients treated with deferasirox (DFX) tablets, desferioxamine (DFO) vial, or combination of both (DFX + DFO) in thalassemia center/Karbala. Al-Mustaqbal J Pharm Med Sci. 2024;2(1):37-43.

Faruqi A, Zafar T, Subuctageen S, Mughal IA. Iron overload and liver function in patients with beta thalassemia major: A cross sectional study. Pak J Med Sci. 2024;40(9):2000-4.

Angastiniotis M, Eleftheriou A, Naveed M, Al Assaf A, Polynikis A, Soteriades ES, et al. TIF standards for haemoglobinopathy reference centres. Thalass Rep. 2023;13:10-20.

El-Beshlawy A, Dewedar H, Hindawi S, Alkindi S, Tantawy AA, Yassin MA, et al. Management of transfusion-dependent beta-thalassemia: expert insights and practical overview from the Middle East. Blood Rev. 2024;63:101138.

Al-Kuraishy HM, Al-Gareeb AI. Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Asian J Transfus Sci. 2017;11(1):13-8.

Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2017;(8):CD007476.

Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-7.

Bajwa H, Basit H. Thalassemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, et al. Long-term safety and efficacy of deferasirox in pediatric patients with β-thalassemia major. Eur J Haematol. 2012;88(5):431-8.

Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, et al. Deferasirox-deferoxamine combination therapy reduces cardiac iron overload in patients with transfusion-dependent thalassemia. Blood. 2013;122(21):2257.

Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P, et al. Combination therapy with deferasirox and deferoxamine in patients with thalassemia major. Transfus Med. 2015;25(1):8-12.

Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood. 2009;114(21):4632-8.

Faranoush M, Faranoush P, Heydari I, Ahmadi A, Shafiee A, Ghasemi A, et al. Clinical complications in patients with transfusion-dependent thalassemia: a multicenter study. Health Sci Rep. 2023;6:e1410.

Forni GL, Gianesin B, Musallam KM, Longo F, Rosso R, Lisi R, et al. Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years. Am J Hematol. 2023;98(3):381-7.